FeesSafety
Pluang+

GT Biopharma reports Q3 2026 results, advancing Phase 1 trials with $10M cash runway into Q3 2027

Company Fundamentals
16 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
GT Biopharma reports Q3 2026 results, advancing Phase 1 trials with $10M cash runway into Q3 2027

GT Biopharma announced its third quarter 2026 financial results, highlighting ongoing Phase 1 trials for its TriKE® immuno-oncology therapies GTB-3650 and GTB-5550 targeting blood cancers and solid tumors. The company received FDA clearance for a new IND to test GTB-5550 in multiple myeloma, expanding its therapeutic reach. With approximately $10 million in cash as of September 30, 2026, GT Biopharma expects to fund operations into Q3 2027. Updates on both Phase 1 trials are anticipated in Q4 2026, reflecting progress in clinical development and potential future growth.

GT Biopharma's Q3 2026 financial results provide context for readers. For those following health-sector stocks, 66 of 150 rose and 50 fell on Pluang today. Notable movers include ABEO at USD 2.28 with a -5.79% change, ENVB at USD 1.58 with +4.29%, and TWST at USD 106.90 with -4.21%. Data is as of Nov 16, 2026 18:12 WIB.

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
20 minutes ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
20 minutes ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
20 minutes ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App